SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:20b113cf-8830-4de6-8689-68a215af300b"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:20b113cf-8830-4de6-8689-68a215af300b" > Entinostat Enhances...

Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

Solta, Anna (författare)
Medical University of Vienna
Boettiger, Kristiina (författare)
Medical University of Vienna
Kovács, Ildikó (författare)
National Korányi Institute for Tuberculosis and Pulmonology, Hungary
visa fler...
Lang, Christian (författare)
Medical University of Vienna
Megyesfalvi, Zsolt (författare)
Medical University of Vienna
Ferk, Franziska (författare)
Medical University of Vienna
Mišík, Miroslav (författare)
Medical University of Vienna
Hoetzenecker, Konrad (författare)
Medical University of Vienna
Aigner, Clemens (författare)
Medical University of Vienna
Kowol, Christian R (författare)
University of Vienna
Knasmueller, Siegfried (författare)
Medical University of Vienna
Grusch, Michael (författare)
Medical University of Vienna
Szeitz, Beáta (författare)
Semmelweis University
Rezeli, Melinda (författare)
Lund University,Lunds universitet,Avdelningen för Biomedicinsk teknik,Institutionen för biomedicinsk teknik,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Biomedical Engineering,Departments at LTH,Faculty of Engineering, LTH
Dome, Balazs (författare)
Medical University of Vienna
Schelch, Karin (författare)
Medical University of Vienna
visa färre...
 (creator_code:org_t)
2023
2023
Engelska 16 s.
Ingår i: Clinical cancer research : an official journal of the American Association for Cancer Research. - 1078-0432. ; 29:22, s. 4644-4659
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • PURPOSE: Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.EXPERIMENTAL DESIGN: The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.RESULTS: Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.

Ämnesord

TEKNIK OCH TEKNOLOGIER  -- Industriell bioteknik -- Medicinsk bioteknik (hsv//swe)
ENGINEERING AND TECHNOLOGY  -- Industrial Biotechnology -- Medical Biotechnology (hsv//eng)

Nyckelord

Humans
Small Cell Lung Carcinoma/drug therapy
Cisplatin
Lung Neoplasms/pathology
Proteomics
Apoptosis
Histone Deacetylase Inhibitors/pharmacology
DNA Repair
Cell Line, Tumor

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy